- Molecular NameDesloratadine
- SynonymDescarboethoxyloratadine; Descarboethoxyoratidine; desloratadine; Desloratidine
- Weight310.828
- Drugbank_IDDB00967
- ACS_NO100643-71-8
- Show 3D model
- LogP (experiment)N/A
- LogP (predicted, AB/LogP v2.0)3.76
- pkaN/A
- LogD (pH=7, predicted)1.09
- Solubility (experiment)Slightly soluble
- LogS (predicted, ACD/Labs)(ph=7)-1.86
- LogSw (predicted, AB/LogsW2.0)0.01
- Sw (mg/ml) (predicted, ACD/Labs)0.03
- No.of HBond Donors1
- No.of HBond Acceptors2
- No.of Rotatable Bonds0
- TPSA24.92
- StatusFDA approved
- AdministrationN/A
- PharmacologyA drug used to treat allergies.
- Absorption_valueN/A
- Absorption (description)N/A
- Caco_2N/A
- BioavailabilityN/A
- Protein binding85.0
- Volume of distribution (VD)N/A
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmMetabolised to digoxin.
- Half life27 h
- ExcretionAfter IV administration, about 80% of a single dose is excreted in the urine in 72 h, mostly as unchanged drug, and about 10% of a dose is eliminated in the faeces. During maintenance treatment, about 30% of a daily dose is excreted in the 24-h urine. After oral administration digoxin accounts for about 50% of the total urinary excretion material. Deslanoside is a metabolite of lanatoside C.
- Urinary ExcretionN/A
- Clerance114-201 l/h
- ToxicityThe adverse events reported by 2% or more of allergic rhinitis patients are pharyngitis, dry mouth, myalgia, fatigue, somnolence, dysmenorrhea.
- LD50 (rat)N/A
- LD50 (mouse)N/A